NEDD4: A Promising Target for Cancer Therapy
Xiantao Ye, Lixia Wang, Bingxue Shang, Zhiwei Wang and Wenyi Wei
Affiliation: Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, USA.
The Neuronally expressed developmentally downregulated 4 (NEDD4), functioning largely as an E3 ubiquitin
ligase, has been demonstrated to play a critical role in the development and progression of human cancers. In this review,
to understand the regulatory mechanism(s) of NEDD4 as well as the signaling pathways controlled by NEDD4, we briefly
describe the NEDD4 upstream regulators and its downstream ubiquitin substrates. Moreover, we further discuss its
oncogenic roles in human malignancies. Therefore, targeting NEDD4 could be a potential therapeutic strategy for
treatment of human cancers.
Keywords: Cancer, E3 ligase, NEDD4, oncogene, target, therapy, ubiquitination.
Rights & PermissionsPrintExport